Evidence map›Paper›PMID 33426223›Full record

ArticleRegenerative therapy2020

Proteomic analysis of platelet-rich and platelet-poor plasma.

Olga Miroshnychenko, Robert J Chalkley, Ryan D Leib, Peter A Everts, Jason L Dragoo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Regenerative therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Manufacture and Initial Characterisation of RAPIDGels (Basel, Switzerland) · 2024
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Olga MiroshnychenkoDepartment of Orthopaedic Surgery, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA, 94305-5341, USA.
Robert J ChalkleyMass Spectrometry Facility, University of California, San Francisco, 600 16th Street, Genentech Hall, suite N472A, San Francisco, CA, 94143-2240, USA.
Ryan D LeibVincent Coates Foundation Mass Spectrometry Laboratory, Stanford University, 333 Campus Dr., Mudd Building, room 175, Stanford, CA 94305-4401, USA.
Peter A EvertsGulf Coast Biologics. 4331 Veronica S. Shoemaker Blvd., Suite 2, Fort Myers, FL, 33916, USA.
Jason L DragooSports Medicine Center, 450 Broadway St., Pavilion C, Room C-433, MC 6120, Redwood City, CA, 94063, USA.
Stanford University · USFlorida Gulf Coast University · USUniversity of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAutologous blood products, such as platelet-rich plasma (PRP) are commercial products broadly used to accelerate healing of tissues after injuries. However, their content is not standardized and significantly varies in composition, which may lead to differences in clinical efficacy. Also, the underlying molecular mechanisms for therapeutic effects are not well understood. PURPOSE: A proteomic study was performed to compare the composition of low leukocyte PRP, platelet poor plasma (PPP), and blood plasma. Pathway analysis of the proteomic data was performed to evaluate differences between plasma formulations at the molecular level. Low abundance regulatory proteins in plasma were identified and quantified as well as cellular pathways regulated by those proteins.

methodsQuantitative proteomic analysis, using multiplexed isotopically labeled tags (TMT labeling) and label-free tandem mass spectrometry, was performed on plasma, low leukocyte PRP, and PPP. Plasma formulations were derived from two blood donors (one donor per experiment). Pathway analysis of the proteomic data identified the major differences between formulations.

resultsNearly 600 proteins were detected in three types of blood plasma formulations in two experiments. Identified proteins showed more than 50% overlap between plasma formulations. Detected proteins represented more than 100 canonical pathways, as was identified by pathway analysis. The major pathways and regulatory molecules were linked to inflammation.

conclusionThree types of plasma formulations were compared in two proteomic experiments. The most represented pathways, such as Acute Phase Response, Coagulation, or System of the Complement, had many proteins in common in both experiments. In both experiments plasma sample sets had the same direction of biochemical pathway changes: up- or down-regulation. The most represented biochemical pathways are linked to inflammation.

Indexed as

And cytokinesBlood productGrowth factorsPathway analysisPPPPRP

Identifiers

PMID33426223
PMCPMC7770407
OpenAlexW3095746537

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.